Mainz Biomed B.V. (MYNZ) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Mainz Biomed B.V.

MYNZ

NASDAQ

Unprofitable

Medical - Diagnostics & Research

Next Earning date - 01 Jul 2025

Medical - Diagnostics & Research

Next Earning date - 01 Jul 2025

2.50USD

-0.05 ( -1.96%)

Market Open

Relative Strenght

Volume Buzz

-82%

Earning Acce

Dist 52w H.

70%

Overview Chart

Quote Panel

Updated May 9, 2025

1W -11.03 % 1M -22.36 % 3M -64.74 % 1Y -90.53 %

Key Metrics

Market Cap
7.60M
Shares Outstanding
3.04M
Share in Float
2.89M
Dividende
0

Earning Date
01 Jul 2025
Price Target
2.5
Average Volume
244377
Beta
0.506

Range
0.18-8.2
Industry
Medical - Diagnostics & Research
Website
https://mainzbiomed.com
Sector
Healthcare

Quote Panel

Updated May 9, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

10.54x

P/S Ratio

0.24x

P/B Ratio

0.5

Debt/Equity

-2203.4%

Net Margin

$-22.4

EPS

How MYNZ compares to sector?

P/E Ratio

Fundamentals

Relative Strength

MYNZ

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

MYNZ

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$1M

112%

2025-Revenue

$3.90

80%

2025-EPS

$999K

89%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Hold

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q2.21

N/A

-0.02
vs -0.01

Q4.21

N/A

-1.30
vs -0.01

Q2.22

N/A

-0.97
vs -0.02

Q4.22

N/A

-18.00
vs -1.30

Q2.23

N/A

-15.60
vs -0.97

Q4.23

N/A

-9.60
vs -18.00

Q2.24

N/A

-15.60
vs -15.60

Q3.24

N/A

-5.20
vs NA

Q4.24

N/A

-3.60
vs -9.60

Sales Growth

YoY

Current

Estimates

Q2.21

+69%

417.3K vs 246.8K

Q4.21

-35%

160K vs 246.8K

Q2.22

-33%

278.5K vs 417.3K

Q4.22

+57%

251.4K vs 160K

Q2.23

+80%

500.2K vs 278.5K

Q4.23

-15%

214.8K vs 251.4K

Q2.24

+4%

520.8K vs 500.2K

Q3.24

600K vs NA

Q4.24

+147%

531.2K vs 214.8K

Return on Equity

QoQ

Q2.21

+10%

0.1
vs 0.11

Q4.21

-180%

-1.80
vs 0.1

Q2.22

-58%

-0.58
vs -1.80

Q4.22

-89%

-0.89
vs -0.58

Q2.23

-256%

-2.56
vs -0.89

Q4.23

-160%

-1.60
vs -2.56

Q2.24

+266%

2.66
vs -1.60

Q4.24

NA
vs 2.66

Institutionnal Ownership

QoQ

Q4.22

6
vs 4

50%

Q1.23

6
vs 6

Q2.23

9
vs 6

50%

Q3.23

8
vs 9

-11%

Q4.23

11
vs 8

38%

Q1.24

12
vs 11

Q2.24

9
vs 12

-25%

Q3.24

11
vs 9

22%

Earnings Growth

Latest News

globenewswire.com

8 hours ago

Mainz Biomed Enters into Technology Partnership with EDX Medical Group

globenewswire.com

8 hours ago

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

globenewswire.com

8 hours ago

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

globenewswire.com

8 hours ago

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

globenewswire.com

8 hours ago

Mainz Biomed Expands into Switzerland with labor team w

globenewswire.com

9 hours ago

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Company Description

2.50USD

N/A

10.54x

0.24x

0.5

-2203.4%

$-22.4

$1M

$3.90

$999K

Earnings Growth

Latest News

Latest News

Latest News

N/A

10.54x

0.24x

0.5

-2203.4%

$-22.4

Company Description

2.50USD

$1M

$3.90

$999K